Hippolyte Fofack’s piece emphasizes shifting from disease-centered models to enhancing healthspan. Using examples such as senolytic drugs and rapamycin, the article discusses global demographic changes and policy implications. It illustrates how innovative research can drive economic stability and improved public health outcomes.
Q&A
- What is healthspan?
- How do anti-aging drugs work?
- What economic impact does extending healthspan have?